SUO 2017: The Utilization of Hormone Therapy and Chemotherapy
Washington, DC (UroToday.com) Dr. Schober and colleagues from the Lahey Clinic provided an analysis of the impact of insurance status on utilization of hormone therapy and chemotherapy for men with metastatic prostate cancer. Previous studies have documented an increased risk of presenting with metastatic prostate cancer for men with no insurance or suboptimal coverage . Treatment options for metastatic prostate cancer have significantly expanded during the past decade, including the first-line use of docetaxel in selected men with newly-diagnosed metastatic prostate cancer [2-4]. The objective of this study was to describe treatment patterns of metastatic prostate cancer over the past decade, specifically the utilization of hormone and chemotherapy, according to insurance status.
SUO 2017: Analysis Defining Optimal Management of Clinical Stage 1 High-Risk Nonseminomatous Germ Cell Testicular Cancer
Washington, DC (UroToday.com) The standard of care for clinical stage non-seminomatous germ cell testicular cancer (NSGCT) is active surveillance, single dose chemotherapy (BEP x 1) or primary RPLND. While most favor active surveillance for all CS1 NSGCT, some centers favor a risk stratification approach. For patients with high-risk features, such as presence of lymphovascular invasion (LVI), they would favor BEP x 1 rather than AS. However, there are good arguments for and against both approaches.
SUO 2017: Impact of Variant Histology on Response to Neoadjuvant Chemotherapy for Bladder Cancer
Washington, DC (UroToday.com) Dr. Lin-Brande and colleagues presented their work assessing the impact of variant histology response to neoadjuvant chemotherapy (NAC) for patients with bladder cancer. Based on randomized clinical trial data, NAC provides a survival benefit for patients with pure urothelial carcinoma1, however it is unclear if histologic variants receive the same benefit. The objective of this study was to assess the ability of NAC to downstage patients with variant histology prior to radical cystectomy (RC) and to quantify variant subtype, extravesicular involvement, and overall survival (OS) for histologic variants.
SUO 2017: Patient-Centered Health Information Self-Education Tool Supporting Recovery After Cystectomy and Urinary Diversion
Washington, DC (UroToday.com) Dr. Peyton and colleagues presented their research assessing a patient-centered health information self-education tool for patients after radical cystectomy and urinary diversion. Given the morbidity associated with undergoing a radical cystectomy and the paucity of patient centered educational interventions, these initiatives are needed. The objective of this study was to develop a patient-centered health information self-education tool.
SUO 2017: 68 GA-PSMA PET/CT Versus MP-MRI For Locoregional Prostate Cancer Staging: Correlation With Final Histopathology
Washington, DC (UroToday.com) Introduction: It is well known that prostate-specific membrane antigen (PSMA) positron emission tomography (PET) can be used to locate lesions based on PSMA avidity.
SUO 2017: Enhanced Recovery After Surgery (ERAS) Protocol for Patients Undergoing Radical Cystectomy
Washington, DC (UroToday.com) Dr. Chen and colleagues presented their research assessing the enhanced recovery after surgery (ERAS) protocol for patients undergoing radical cystectomy (RC). ERAS pathways have significantly reduced complications and length of hospital stay after colorectal procedures and similar concepts have been applied to major urological procedures, including RC1. The objective of this study was to determine whether surgical approach is a determinant factor for clinical outcomes after RC and urinary diversion using an ERAS protocol.
SUO 2017: Utilization of MRI and Genomic Markers in Surveillance and Treatment Selection Among Patients Diagnosed With Prostate Cancer
Washington, DC (UroToday.com) Introduction: Contemporary assessment tools for patients with prostate cancer (PCa) include genomic marker testing, and multiparametric magnetic resonance imaging (mp−MRI).